Clinical Research Directory
Browse clinical research sites, groups, and studies.
Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration
Sponsor: Universidad Nacional Autonoma de Mexico
Summary
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis
Official title: Towards the Improvement of the Treatment of Acute Relapses in Multiple Sclerosis: A Randomized Double-blind, Non-inferiority Controlled Trial Comparing Intranasal Versus Intravenous Methylprednisolone
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2023-01-09
Completion Date
2026-07-05
Last Updated
2025-04-03
Healthy Volunteers
No
Interventions
IV Methylprednisolone administration
Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse
Nasal Methylprednisolone (MT)
Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse
Locations (1)
Instituto Nacional de Neurología y Neurocirugía
Mexico City, Mexico